News
Stockhead on MSN51m
Neurizon’s ALS drug shows safety and extended survival in open-label extension study
Neurizon Therapeutics has reported positive topline results from an open-label extension study of its lead candidate NUZ-001 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback